Summarized by Masters of Longevity from Longevity Technology.
Report on a Florida biotech acquiring a pulmonary hypertension developer and securing $350 million to advance lung-focused therapeutics and related governance changes.
Key Takeaways
- Alaunos acquired Velaris to add a pulmonary arterial hypertension drug program.
- The company raised $350 million to fund development through approximately 2029.
- Fairmount investors would control the board if preferred stock is converted.
